James B Dale
- Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related proteinHarry S Courtney
Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, TN 38104, USA
Mol Microbiol 59:936-47. 2006..This may be a common mechanism for evasion of phagocytosis because Mrp is expressed by approximately half of the clinical isolates of S. pyogenes...
- Current status of group A streptococcal vaccine developmentJames B Dale
University of Tennessee Health Science Center, Memphis 38104, USA
Adv Exp Med Biol 609:53-63. 2008..Successful deployment of safe and effective vaccines to prevent GAS infections and their complications could potentially have a significant impact on the health of millions of people around the world...
- Potential coverage of a multivalent M protein-based group A streptococcal vaccineJames B Dale
University of Tennessee Health Science Center, Department of Medicine and Veterans Affairs Medical Center Research Service, Memphis, TN, USA
Vaccine 31:1576-81. 2013..The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD...
- Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infectionsMary A Hall
Department of Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA
Infect Immun 72:2507-12. 2004..Our results indicate that intranasal delivery of adjuvanted multivalent M protein vaccines induces protective antibody responses and may provide an alternative to parenteral vaccine formulations...
- Group A streptococcal vaccines: paving a path for accelerated developmentJames B Dale
University of Tennessee Health Science Center, Memphis, TN 38163, USA
Vaccine 31:B216-22. 2013..Specific recommendations are presented for an accelerated plan leading to the introduction of a broadly protective vaccine designed for deployment in low-, middle-, and high-income countries...
- The NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of miceThomas A Penfound
Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
J Infect Dis 201:1580-8. 2010..The NH(2)-terminal sequence of the M protein from group A streptococci defines the serotype of the organism and contains epitopes that evoke bactericidal antibodies...
- Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypesJames B Dale
Department of Veterans Affairs, The University of Health Science Center, Memphis, TN 38104, USA
Clin Diagn Lab Immunol 12:833-6. 2005....
- Southern Society for Clinical Investigation Founders' Medal recipient's addressJames B Dale
University of Tennessee College of Medicine, Memphis, USA
Am J Med Sci 324:61-6. 2002
- Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococciJames B Dale
Department of Veterans Affairs Medical Center and Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA
Infect Immun 70:2166-70. 2002..Our data also provide convincing evidence that the sagA gene actually encodes the SLS peptide of GAS. The synthetic peptide may prove to be an important component of vaccines designed to prevent GAS infections...
- Progress in group A streptococcal vaccine developmentKaren L Kotloff
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
Pediatr Infect Dis J 23:765-6. 2004
- Immunogenicity of a 26-valent group A streptococcal vaccineMary C Hu
ID Biomedical Corporation, Bothell, Washington, USA
Infect Immun 70:2171-7. 2002..Our results indicate that type-specific, protective M protein epitopes can be incorporated into complex, multivalent vaccines designed to elicit broadly protective opsonic antibodies in the absence of tissue-cross-reactive antibodies...
- Dynamic epidemiology of group A streptococcal serotypesJames B Dale
Lancet 359:889. 2002
- Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United StatesStanford T Shulman
Division of Infectious Diseases, Children s Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Clin Infect Dis 42:441-7. 2006..It has been proposed that certain M types of group A streptococci (GAS) include strains that are particularly rheumatogenic and that others are nonrheumatogenic...
- Molecular mechanisms of adhesion, colonization, and invasion of group A streptococciHarry S Courtney
Veterans Affairs Medical Center, Department of Medicine, Memphis, TN, USA
Ann Med 34:77-87. 2002..In this review, we present the different molecular mechanisms of adhesion utilized by group A streptococci and how these interactions lead to colonization and invasion...
- Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshopAlan L Bisno
University of Miami Miller School of Medicine, Miami, Florida 33125, USA
Clin Infect Dis 41:1150-6. 2005..This report summarizes the deliberations of the workshop...
- Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteersShelly A McNeil
Clinical Trials Research Center, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada
Clin Infect Dis 41:1114-22. 2005..New molecular techniques have allowed the previous obstacles to be largely overcome...
- Presentation of the Southern Society for Clinical Investigation 2002 Founders' Medal to Dr. James B. DaleAndrew H Kang
Department of Medicine, University of Tennessee College of Medicine, Memphis 39163, USA
Am J Med Sci 324:57-60. 2002
- Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococciHarry S Courtney
Veterans Affairs Medical Center and Department of Medicine, University of Tennessee, Memphis, Tennessee 38104, USA
Infect Immun 71:5097-103. 2003....
- Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trialKaren L Kotloff
Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA
JAMA 292:709-15. 2004..Group A streptococcal infections and their sequelae represent a global health problem. Recent advances have allowed previous obstacles associated with group A streptococcal vaccine development to be overcome...
- Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002Stanford T Shulman
Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL, USA
Clin Infect Dis 39:325-32. 2004....
- Mapping the fibrinogen-binding domain of serum opacity factor of group a streptococciHarry S Courtney
Department of Medicine, University of Tennessee, Memphis, TN, USA
Curr Microbiol 44:236-40. 2002..These data suggest that fibrinogen and fibronectin bind to the same domain within SOF. It remains to be determined whether the binding of fibrinogen to SOF contributes to the virulence of group A streptococci...
- The importance of the group a streptococcus capsule in the pathogenesis of human infections: a historical perspectiveGene H Stollerman
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
Clin Infect Dis 46:1038-45. 2008..We believe that it is time to refocus newer clinical studies and techniques on achieving early recognition of potentially dangerous, heavily encapsulated strains of GAS for which spread may be prevented...